FDA approves botulinum toxin A to reduce appearance of wrinkles

07/26/2011 | SkinAndAllergyNews.com

The FDA approved Merz Aesthetics' Xeomin, or incobotulinumtoxinA, for temporarily reducing skin lines and wrinkles. The product is expected to be available in the U.S. next year. Dermatologist and trial investigator Joel Cohen said incobotulinumtoxinA is "more similar than it is different to other products that are on the market, particularly Botox."

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ